197 related articles for article (PubMed ID: 33420372)
21. Regulation of STAT3 and NF-κB activations by S-nitrosylation in multiple myeloma.
Kim J; Choi S; Saxena N; Singh AK; Singh I; Won JS
Free Radic Biol Med; 2017 May; 106():245-253. PubMed ID: 28232202
[TBL] [Abstract][Full Text] [Related]
22. Roles of Pin1 as a Key Molecule for EMT Induction by Activation of STAT3 and NF-κB in Human Gallbladder Cancer.
Nakada S; Kuboki S; Nojima H; Yoshitomi H; Furukawa K; Takayashiki T; Takano S; Miyazaki M; Ohtsuka M
Ann Surg Oncol; 2019 Mar; 26(3):907-917. PubMed ID: 30610554
[TBL] [Abstract][Full Text] [Related]
23. Small-molecule inhibitors targeting the DNA-binding domain of STAT3 suppress tumor growth, metastasis and STAT3 target gene expression in vivo.
Huang W; Dong Z; Chen Y; Wang F; Wang CJ; Peng H; He Y; Hangoc G; Pollok K; Sandusky G; Fu XY; Broxmeyer HE; Zhang ZY; Liu JY; Zhang JT
Oncogene; 2016 Feb; 35(6):783-92. PubMed ID: 26073084
[TBL] [Abstract][Full Text] [Related]
24. Novel STAT3 phosphorylation inhibitors exhibit potent growth-suppressive activity in pancreatic and breast cancer cells.
Lin L; Hutzen B; Zuo M; Ball S; Deangelis S; Foust E; Pandit B; Ihnat MA; Shenoy SS; Kulp S; Li PK; Li C; Fuchs J; Lin J
Cancer Res; 2010 Mar; 70(6):2445-54. PubMed ID: 20215512
[TBL] [Abstract][Full Text] [Related]
25. A cell-permeable Stat3 SH2 domain mimetic inhibits Stat3 activation and induces antitumor cell effects in vitro.
Zhao W; Jaganathan S; Turkson J
J Biol Chem; 2010 Nov; 285(46):35855-65. PubMed ID: 20807764
[TBL] [Abstract][Full Text] [Related]
26. Alantolactone sensitizes human pancreatic cancer cells to EGFR inhibitors through the inhibition of STAT3 signaling.
Zheng H; Yang L; Kang Y; Chen M; Lin S; Xiang Y; Li C; Dai X; Huang X; Liang G; Zhao C
Mol Carcinog; 2019 Apr; 58(4):565-576. PubMed ID: 30520143
[TBL] [Abstract][Full Text] [Related]
27. LB-1 Exerts Antitumor Activity in Pancreatic Cancer by Inhibiting HIF-1α and Stat3 Signaling.
Niu F; Li Y; Lai FF; Ni L; Ji M; Jin J; Yang HZ; Wang C; Zhang DM; Chen XG
J Cell Physiol; 2015 Sep; 230(9):2212-23. PubMed ID: 25655308
[TBL] [Abstract][Full Text] [Related]
28. MiR-1181 inhibits stem cell-like phenotypes and suppresses SOX2 and STAT3 in human pancreatic cancer.
Jiang J; Li Z; Yu C; Chen M; Tian S; Sun C
Cancer Lett; 2015 Jan; 356(2 Pt B):962-70. PubMed ID: 25444909
[TBL] [Abstract][Full Text] [Related]
29. Bufalin inhibits pancreatic cancer by inducing cell cycle arrest via the c-Myc/NF-κB pathway.
Liu X; Xiao XY; Shou QY; Yan JF; Chen L; Fu HY; Wang JC
J Ethnopharmacol; 2016 Dec; 193():538-545. PubMed ID: 27686271
[TBL] [Abstract][Full Text] [Related]
30. Targeting mitochondrial STAT3 with the novel phospho-valproic acid (MDC-1112) inhibits pancreatic cancer growth in mice.
Mackenzie GG; Huang L; Alston N; Ouyang N; Vrankova K; Mattheolabakis G; Constantinides PP; Rigas B
PLoS One; 2013; 8(5):e61532. PubMed ID: 23650499
[TBL] [Abstract][Full Text] [Related]
31. Targeting the Janus-activated kinase-2-STAT3 signalling pathway in pancreatic cancer using the HSP90 inhibitor ganetespib.
Nagaraju GP; Mezina A; Shaib WL; Landry J; El-Rayes BF
Eur J Cancer; 2016 Jan; 52():109-19. PubMed ID: 26682870
[TBL] [Abstract][Full Text] [Related]
32. Arginine deiminase augments the chemosensitivity of argininosuccinate synthetase-deficient pancreatic cancer cells to gemcitabine via inhibition of NF-κB signaling.
Liu J; Ma J; Wu Z; Li W; Zhang D; Han L; Wang F; Reindl KM; Wu E; Ma Q
BMC Cancer; 2014 Sep; 14():686. PubMed ID: 25240403
[TBL] [Abstract][Full Text] [Related]
33. Shikonin-mediated PD-L1 degradation suppresses immune evasion in pancreatic cancer by inhibiting NF-κB/STAT3 and NF-κB/CSN5 signaling pathways.
Ruan Z; Liang M; Shang L; Lai M; Deng X; Su X
Pancreatology; 2021 Apr; 21(3):630-641. PubMed ID: 33707115
[TBL] [Abstract][Full Text] [Related]
34. Ursolic acid inhibits multiple cell survival pathways leading to suppression of growth of prostate cancer xenograft in nude mice.
Shanmugam MK; Rajendran P; Li F; Nema T; Vali S; Abbasi T; Kapoor S; Sharma A; Kumar AP; Ho PC; Hui KM; Sethi G
J Mol Med (Berl); 2011 Jul; 89(7):713-27. PubMed ID: 21465181
[TBL] [Abstract][Full Text] [Related]
35. Blockage of STAT3 Signaling Pathway by Morusin Induces Apoptosis and Inhibits Invasion in Human Pancreatic Tumor Cells.
Kim C; Kim JH; Oh EY; Nam D; Lee SG; Lee J; Kim SH; Shim BS; Ahn KS
Pancreas; 2016 Mar; 45(3):409-19. PubMed ID: 26646273
[TBL] [Abstract][Full Text] [Related]
36. Cotargeting of MEK and PDGFR/STAT3 Pathways to Treat Pancreatic Ductal Adenocarcinoma.
Sahu N; Chan E; Chu F; Pham T; Koeppen H; Forrest W; Merchant M; Settleman J
Mol Cancer Ther; 2017 Sep; 16(9):1729-1738. PubMed ID: 28619758
[TBL] [Abstract][Full Text] [Related]
37. LLY17, a novel small molecule STAT3 inhibitor induces apoptosis and suppresses cell migration and tumor growth in triple-negative breast cancer.
Pan L; Chen X; Fu S; Yu W; Li C; Wang T; Lo HW; Lin J
Breast Cancer Res Treat; 2020 May; 181(1):31-41. PubMed ID: 32240456
[TBL] [Abstract][Full Text] [Related]
38. A preclinical evaluation of SKLB261, a multikinase inhibitor of EGFR/Src/VEGFR2, as a therapeutic agent against pancreatic cancer.
Pan Y; Zheng M; Zhong L; Yang J; Zhou S; Qin Y; Xiang R; Chen Y; Yang SY
Mol Cancer Ther; 2015 Feb; 14(2):407-18. PubMed ID: 25519702
[TBL] [Abstract][Full Text] [Related]
39. Down-regulation of STAT3 expression by vector-based small interfering RNA inhibits pancreatic cancer growth.
Huang C; Yang G; Jiang T; Cao J; Huang KJ; Qiu ZJ
World J Gastroenterol; 2011 Jul; 17(25):2992-3001. PubMed ID: 21799645
[TBL] [Abstract][Full Text] [Related]
40. A novel small molecule, LLL12, inhibits STAT3 phosphorylation and activities and exhibits potent growth-suppressive activity in human cancer cells.
Lin L; Hutzen B; Li PK; Ball S; Zuo M; DeAngelis S; Foust E; Sobo M; Friedman L; Bhasin D; Cen L; Li C; Lin J
Neoplasia; 2010 Jan; 12(1):39-50. PubMed ID: 20072652
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
